All reovirus subtypes show oncolytic potential in primary cells of human high-grade glioma

Oncology Reports

Volumn 26, Issue 3, 2011, Pages 645-649

  Alloussi, Saladin Helmut ^a,b   Alkassar, M ^a   Urbschat, S ^a   Graf, N ^a   Gartner B ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Glioblastoma; Reovirus; Virotherapy

Indexed keywords

ONCOLYTIC VIRUS; RAS PROTEIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN BIOPSY; CANCER GRADING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG EFFICACY; DRUG SCREENING; FEMALE; GENE ACTIVITY; GENE OVEREXPRESSION; GLIOMA; GLIOMA CELL; HIGH GRADE GLIOMA; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IN VITRO STUDY; MALE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; REOVIRUS; VIRUS TYPING;

AGED; BRAIN NEOPLASMS; CELL SURVIVAL; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; ONCOLYTIC VIROTHERAPY; REOVIRIDAE; TUMOR CELLS, CULTURED; VIRAL LOAD;

EID: 79959961030     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1331     Document Type: Article

References (17)

1. Arvanitis D, Malliri A, Antoniou D, Linardopoulos S, Field JK and Spandidos DA: Ras p21 expression in brain tumors: elevated expression in malignant astrocytomas and glioblastomas multiforme. In Vivo 5: 317-321, 1991.
2. Gomori E, Doczi T, Pajor L and Matolcsy A: Sporadic p53 mutations and absence of ras mutations in glioblastomas. Acta Neurochir (Wien) 141: 593-599, 1999. (Pubitemid 29281482)
3. Guha A, Feldkamp MM, Lau N, Boss G and Pawson A: Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene 15: 2755-2765, 1997. (Pubitemid 28004565)
4. Orian JM, Vasilopoulos K, Yoshida S, Kaye AH, Chow CW and Gonzales MF: Overexpression of multiple oncogenes related to histological grade of astrocytic glioma. Br J Cancer 66: 106-112, 1992.
5. Wilcox ME, Yang W, Senger D, et al: Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst 93: 903-912, 2001. (Pubitemid 32624647)
6. Yamamoto T, Taya S and Kaibuchi K: Ras-induced transformation and signaling pathway. J Biochem 126: 799-803, 1999.
7. Kiaris H and Spandidos DA: Mutations of ras genes in human tumours (Review). Int J Oncol 7: 413-421, 1995.
8. Gollamudi R, Ghalib MH, Desai KK, et al Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs 28: 641-649, 2010.
9. Thagard P: Curing Cancer? Patrick Lee's path to the reovirus treatment. Intern Stud Phil Science 16: 179-193, 2002.
10. Strong JE, Coffey MC, Tang D, Sabinin P and Lee PW: The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 17: 3351-3362, 1998. (Pubitemid 28279509)
11. Marcato P, Shmulevitz M, Pan D, Stoltz D and Lee PW: Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity and apoptosis-dependent release. Mol Ther 15: 1522-1530, 2007. (Pubitemid 47099309)
12. Jacobs BL and Ferguson RE: The Lang strain of reovirus serotype 1 and the Dearing strain of reovirus serotype 3 differ in their sensitivities to beta interferon. J Virol 65: 5102-5104, 1991.
13. Keay L: The growth of L-cells and Vero cells on an autoclavable MEM-peptone medium. Biotechnol Bioeng 19: 399-411, 1977.
14. Coffey MC, Strong JE, Forsyth PA and Lee PW: Reovirus therapy of tumors with activated Ras pathway. Science 282: 1332-1334, 1998. (Pubitemid 28524498)
15. Shmulevitz M, Marcato P and Lee PW: Activated Ras signaling significantly enhances reovirus replication and spread. Cancer Gene Ther 17: 69-70, 2010.
16. Shmulevitz M, Pan LZ, Garant K, Pan D and Lee PW: Oncogenic Ras promotes reovirus spread by suppressing IFN-beta production through negative regulation of RIG-I signaling. Cancer Res 70: 4912-4921, 2010.
17. Thirukkumaran CM, Nodwell MJ, Hirasawa K, et al: Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic. Cancer Res 70: 2435-2444, 2010.